Amílcar Falcão

Amílcar Falcão holds a degree in Pharmaceutical Sciences, PhD and Aggregate in Pharmacy (Pharmacology Specialty) from the University of Coimbra. Full Professor, Director of the Institute of Interdisciplinary Research, functions that accumulate with those of Vice-Dean of the University of Coimbra (Research). He is a researcher at the Center for Neuroscience and Cell Biology (CNC), where he leads the Pharmacology Group.

 

It has an extensive scientific productivity where there are about 400 publications (articles, book chapters and summaries in indexed journals) and other scientific communications in the form of posters and oral presentations (several dozen by invitation), overwhelmingly international and subject arbitration. He was the thesis supervisor of 15 master's and 8 doctoral students, and is currently responsible for 9 doctoral theses and 3 master's theses. He is regularly invited to perform the function of reviewer, also belonging to the editorial staff of several scientific journals. He has already received several national and international awards that reinforce the visibility and quality of the work he has been developing throughout his career.

 

Having maintained a strong connection with the pharmaceutical industry throughout his professional career, his collaboration with BIAL Laboratories (Portugal) stands out, participating actively and in a relevant way in his program of development of new medicines. Its contribution is to both non-clinical and clinical trials (biostatistics, pharmacokinetics and pharmacodynamics) and has been involved in more than a hundred studies in total. Included in the portfolio are a set of molecules with special emphasis on Eslicarbazepine Acetate, which was the first Portuguese drug to be marketed (Zebinix®) and, more recently, Opicapone (new medicine for Parkinson's disease, currently in Phase III).

 

He is also the Technical Director of ICNAS Produção (a company owned 100% by the University of Coimbra). He participated actively in obtaining the first radiopharmaceutical product developed and registered in Portugal (Fluodeoxyglucose [18F] UC).